A couple new science news that likely won’t impact the share price tomorrow.....NASH P2 approves and Army testing leronlimab for PrEP. As far as financing, NP clearly stated that the license deal is ‘very well alive’ and his legal team told him not to discuss ‘secured financing’.....my take is both are in the works and he won’t address them again until the PR is released. Could very well be that we wake to this PR in the next week or so.

I’m already double what my initial share goal was, but may add more if we see low .30s again. Q4 begins tomorrow and I expect a windfall of news to begin soon and not stop for the foreseeable future once this breaks free.